Lund — 25 May 2018 — Camurus AB (Nasdaq Stockholm; CAMX) today announced that the Company will present at the Jefferies 2018 Healthcare Conference in New York on Tuesday 5 June at 8:30 am local time (EDT). Fredrik Tiberg PhD, President and Chief Executive Officer, will update on the progress on the development pipeline, including the ongoing registration processes of the company’s weekly and monthly buprenorphine depots (CAM2038) under development for treatment of opioid dependence.
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Fredrik Joabsson, VP Business Development
Tel. +46 (0)70 776 17 37
The information was submitted for publication at 08.00 am CET on 25 May 2018.